Product Information
LABETALOL HCL 300 MG TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $0.2046 per EA under NDC 00591060701. Its NADAC has been published 653 times since Nov 28, 2013.
FDA first approved this application on Aug 3, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00591060701
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
LABETALOL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA075133FDA Approved
8/3/1998
TE Code
AB
On Market Since
8/3/1998
Pharmacological Classes
Price Statistics
The NADAC for LABETALOL HCL 300 MG TABLET has been published 653 times since Nov 28, 2013, and over the history we have for it it has declined 65.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2046 per EA |
|---|---|
| All-time high | $0.6120 (Apr 16, 2014) |
| All-time low | $0.1776 (Nov 20, 2024) |
| 52-week high | $0.2100 |
| 52-week low | $0.2041 |
| Median price | $0.2857 |
| Average price | $0.3392 |
| Largest weekly change | +21.9% (Feb 17, 2021) |
| Weeks tracked | 653 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
+0.1%
1Y
-1.6%
3Y
-0.2%
5Y
-13.8%
All
-65.0%
Last surveyed May 27, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Labetalol hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Labetalol hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LABETALOL HCL 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LABETALOL HCL 300 MG TABLET, manufactured by Actavis Pharma, Inc., is $0.2046 per EA (NDC 00591060701), effective May 27, 2026.
How has the price of LABETALOL HCL 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for LABETALOL HCL 300 MG TABLET has declined 65.0%. It has been tracked across 653 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LABETALOL HCL 300 MG TABLET?
Since Nov 28, 2013, the NADAC for LABETALOL HCL 300 MG TABLET has ranged from a low of $0.1776 (Nov 20, 2024) to a high of $0.6120 (Apr 16, 2014), with a median of $0.2857 per EA.
Are there cheaper alternatives to LABETALOL HCL 300 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LABETALOL HCL 300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LABETALOL HCL 300 MG TABLET?
LABETALOL HCL 300 MG TABLET (NDC 00591060701) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.